{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:31:45Z","timestamp":1772692305640,"version":"3.50.1"},"reference-count":158,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.hoc.2024.08.010","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T10:47:19Z","timestamp":1730803639000},"page":"103-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["An Overview of Liver Directed Locoregional Therapies"],"prefix":"10.1016","volume":"39","author":[{"given":"Diederik J.","family":"H\u00f6ppener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelis","family":"Verhoef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9919","key":"10.1016\/j.hoc.2024.08.010_bib1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hoc.2024.08.010_bib2","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/ijc.28625","article-title":"Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis","volume":"134","author":"Bishop","year":"2014","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/CMR.0000000000000332","article-title":"Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors","volume":"27","author":"Tas","year":"2017","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib4","doi-asserted-by":"crossref","first-page":"e32955","DOI":"10.1371\/journal.pone.0032955","article-title":"Time course and pattern of metastasis of cutaneous melanoma differ between men and women","volume":"7","author":"Mervic","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.hoc.2024.08.010_bib5","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26","volume":"123","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1001\/jamaophthalmol.2018.2466","article-title":"Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma","volume":"136","author":"Lane","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw694","article-title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","volume":"28","author":"Lian","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2024.08.010_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2017.05.014","article-title":"Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma","volume":"81","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0002-9610(78)90072-7","article-title":"Survival after liver resection for secondary tumors","volume":"135","author":"Foster","year":"1978","journal-title":"Am J Surg"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1072-7515(98)00225-7","article-title":"Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients","volume":"187","author":"Elias","year":"1998","journal-title":"J\u00a0Am Coll Surg"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s001040050669","article-title":"Ergebnisse der Resektion nichtcolorectaler nichtneuroendokriner Lebermetastasen","volume":"70","author":"Lang","year":"1999","journal-title":"Chirurg"},{"issue":"7","key":"10.1016\/j.hoc.2024.08.010_bib12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R","article-title":"Protracted survival after resection of metastatic uveal melanoma","volume":"89","author":"Aoyama","year":"2000","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib13","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/1097-0142(20001101)89:9<1983::AID-CNCR15>3.0.CO;2-S","article-title":"Surgical therapy for distant metastases of malignant melanoma","volume":"89","author":"Meyer","year":"2000","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib14","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1001\/archsurg.136.8.950","article-title":"Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience","volume":"136","author":"Rose","year":"2001","journal-title":"Arch Surg"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1245\/ASO.2005.06.032","article-title":"Treatment of liver metastases from uveal melanoma","volume":"12","author":"Rivoire","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/01.sla.0000150244.72285.ad","article-title":"Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma","volume":"241","author":"Weitz","year":"2005","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib17","first-page":"524","article-title":"Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model","volume":"244","author":"Adam","year":"2006","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejso.2005.10.006","article-title":"Hepatic resection for malignant melanoma","volume":"32","author":"Crook","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/01.sla.0000217690.65909.9c","article-title":"Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome","volume":"244","author":"Kim","year":"2006","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib20","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1245\/ASO.2006.01.016","article-title":"Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease","volume":"13","author":"Pawlik","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00268-006-0375-z","article-title":"Selected patients with metastatic melanoma may benefit from liver resection","volume":"31","author":"Herman","year":"2007","journal-title":"World J Surg"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib22","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/13651820701769701","article-title":"Liver resection for non-colorectal, non-neuroendocrine metastases: analysis of a multicenter study from Argentina","volume":"9","author":"Lendoire","year":"2007","journal-title":"HPB (Oxford)"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib23","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1136\/bjo.2008.153684","article-title":"Long-term survival of uveal melanoma patients after surgery for liver metastases","volume":"93","author":"Frenkel","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1055\/s-0029-1224601","article-title":"Leberresektion bei nicht kolorektalen, nicht neuroendokrinen Lebermetastasen-ist die Resektion im Rahmen des \"onko-chirurgischen\" Therapiekonzeptes gerechtfertigt?","volume":"134","author":"Lehner","year":"2009","journal-title":"Zentralbl Chir"},{"issue":"11","key":"10.1016\/j.hoc.2024.08.010_bib25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16 years\u2019 experience at the Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib26","doi-asserted-by":"crossref","first-page":"634","DOI":"10.47102\/annals-acadmedsg.V39N8p634","article-title":"Surgical metastasectomy in AJCC stage IV M1c melanoma patients with gastrointestinal and liver metastases","volume":"39","author":"Chua","year":"2010","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.hoc.2024.08.010_bib27","first-page":"S83","article-title":"Multimodal treatments for liver metastases from melanoma: Experience of a single institution","volume":"17","author":"Pilati","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1245\/s10434-009-0677-0","article-title":"Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy","volume":"17","author":"Ripley","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s00534-010-0341-x","article-title":"Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma","volume":"18","author":"Caralt","year":"2011","journal-title":"J\u00a0Hepatobiliary Pancreat Sci"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jamcollsurg.2011.12.048","article-title":"Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis","volume":"214","author":"Groeschl","year":"2012","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/CMR.0b013e32835b70c8","article-title":"Dutch Liver Working G. Hepatic resection for metastatic melanoma in The Netherlands: survival and prognostic factors","volume":"23","author":"de Ridder","year":"2013","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bjophthalmol-2012-302323","article-title":"MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients","volume":"97","author":"Marshall","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jso.23361","article-title":"Liver resection for metastatic melanoma: equivalent survival for cutaneous and ocular primaries","volume":"108","author":"Ryu","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib34","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1499-3872(13)60095-8","article-title":"Treatment of liver metastases from uveal melanoma: a retrospective single-center analysis","volume":"12","author":"Yang","year":"2013","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamcollsurg.2014.04.008","article-title":"A\u00a020-year experience of hepatic resection for melanoma: is there an expanding role?","volume":"219","author":"Faries","year":"2014","journal-title":"J\u00a0Am Coll Surg"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jso.23535","article-title":"The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection","volume":"109","author":"Gomez","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2024.08.010_bib37","first-page":"6633","article-title":"Liver resection in multimodal concepts improves survival of metastatic melanoma: a single-centre case-matched control study","volume":"34","author":"Hau","year":"2014","journal-title":"Anticancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib38","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/jso.23929","article-title":"Liver resection and ablation for metastatic melanoma: A single center experience","volume":"111","author":"Doussot","year":"2015","journal-title":"J\u00a0Surg Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.hoc.2024.08.010_bib39","doi-asserted-by":"crossref","first-page":"S1083","DOI":"10.1245\/s10434-015-4775-x","article-title":"Is Hepatic Resection for Non-colorectal, Non-neuroendocrine Liver Metastases Justified?","volume":"22","author":"Hoffmann","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib40","doi-asserted-by":"crossref","first-page":"e0120569","DOI":"10.1371\/journal.pone.0120569","article-title":"Liver resection for non-colorectal, non-carcinoid, non-sarcoma metastases: a multicenter study","volume":"10","author":"Martel","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib41","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejso.2016.02.019","article-title":"Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma","volume":"42","author":"Mariani","year":"2016","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib42","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s00464-017-5834-0","article-title":"Laparoscopic liver resection for metastatic melanoma","volume":"32","author":"Aghayan","year":"2018","journal-title":"Surg Endosc"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/cjp2.105","article-title":"Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases","volume":"4","author":"Barnhill","year":"2018","journal-title":"J\u00a0Pathol Clin Res"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib44","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.amjsurg.2017.09.030","article-title":"Liver resection for metastases not of colorectal, neuroendocrine, sarcomatous, or ovarian (NCNSO) origin: A multicentric study","volume":"215","author":"Labgaa","year":"2018","journal-title":"Am J Surg"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/cjp2.161","article-title":"Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value","volume":"6","author":"Barnhill","year":"2020","journal-title":"J\u00a0Pathol Clin Res"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib46","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00464-015-4527-9","article-title":"Laparoscopic management of liver metastases from uveal melanoma","volume":"30","author":"Akyuz","year":"2016","journal-title":"Surg Endosc"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib47","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1007\/s00270-016-1336-z","article-title":"Stereotactic Radiofrequency Ablation for Metastatic Melanoma to the Liver","volume":"39","author":"Bale","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.mayocp.2015.10.025","article-title":"Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma","volume":"91","author":"White","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"1077","key":"10.1016\/j.hoc.2024.08.010_bib49","doi-asserted-by":"crossref","first-page":"20170257","DOI":"10.1259\/bjr.20170257","article-title":"Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma","volume":"90","author":"Franceschini","year":"2017","journal-title":"Br J Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/CMR.0000000000000653","article-title":"Phase Ib\/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)","volume":"30","author":"Rozeman","year":"2020","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.hoc.2024.08.010_bib51","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.1988.03410070102037","article-title":"Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge","volume":"260","author":"Mavligit","year":"1988","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib52","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/1097-0142(19951101)76:9<1665::AID-CNCR2820760925>3.0.CO;2-J","article-title":"Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors","volume":"76","author":"Bedikian","year":"1995","journal-title":"Cancer"},{"issue":"3\u20134","key":"10.1016\/j.hoc.2024.08.010_bib53","first-page":"173","article-title":"Chemoembolization of liver metastases from ocular melanoma: Preliminary results","volume":"8","author":"Morassut","year":"1995","journal-title":"Reg Cancer Treat"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00008390-200508000-00011","article-title":"Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study","volume":"15","author":"Patel","year":"2005","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00432-006-0155-z","article-title":"Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival","volume":"133","author":"Vogl","year":"2007","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib56","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archophthalmol.2009.45","article-title":"Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization","volume":"127","author":"Dayani","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib57","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/COC.0b013e3181b4b065","article-title":"Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors","volume":"33","author":"Gupta","year":"2010","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib58","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/j.ejrad.2009.03.064","article-title":"Transarterial chemoembolization of liver metastases in patients with uveal melanoma","volume":"74","author":"Huppert","year":"2010","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib59","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e328334c36e","article-title":"Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome","volume":"20","author":"Schuster","year":"2010","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/07357907.2010.535052","article-title":"Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma","volume":"29","author":"Ahrar","year":"2011","journal-title":"Cancer Invest"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib61","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.2214\/AJR.11.7748","article-title":"Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis","volume":"199","author":"Edelhauser","year":"2012","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2217\/fon.12.191","article-title":"Repetitive chemoembolization of hypovascular liver metastases from the most common primary sites","volume":"9","author":"Farshid","year":"2013","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib63","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.tranon.2014.05.004","article-title":"Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization","volume":"7","author":"Duran","year":"2014","journal-title":"Transl Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib64","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00270-015-1093-4","article-title":"Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications","volume":"38","author":"Carling","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib65","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2214\/AJR.14.14001","article-title":"Uveal Melanoma Metastatic to the Liver: Chemoembolization With 1,3-Bis-(2-Chloroethyl)-1-Nitrosourea","volume":"205","author":"Gonsalves","year":"2015","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CMR.0000000000000129","article-title":"A\u00a0retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments","volume":"25","author":"Valpione","year":"2015","journal-title":"Melanoma Res"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib67","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s00270-017-1651-z","article-title":"Image-Guided Transarterial Chemoembolization With Drug-Eluting Beads Loaded with Doxorubicin (DEBDOX) for Unresectable Hepatic Metastases from Melanoma: Technique and Outcomes","volume":"40","author":"Rostas","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10147-017-1095-0","article-title":"Efficacy and toxicity of transarterial chemoembolization therapy using cisplatin and gelatin sponge in patients with liver metastases from uveal melanoma in an Asian population","volume":"22","author":"Shibayama","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib69","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/COC.0000000000000356","article-title":"Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma","volume":"41","author":"Abbott","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib70","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/1097-0142(19820315)49:6<1243::AID-CNCR2820490628>3.0.CO;2-Y","article-title":"Thermochemotherapy for melanoma metastases in liver","volume":"49","author":"Storm","year":"1982","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00000658-198807000-00004","article-title":"Treatment of cancer of the liver. Twenty years\u2019 experience with infusion and resection in 414 patients","volume":"208","author":"Stehlin","year":"1988","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib72","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/030089169408000107","article-title":"Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study","volume":"80","author":"Cantore","year":"1994","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/PL00012075","article-title":"Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients","volume":"6","author":"Egerer","year":"2001","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib74","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.bjc.6600521","article-title":"Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2","volume":"87","author":"Becker","year":"2002","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib75","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/01.cmr.0000129377.22141.ea","article-title":"Phase I\/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver","volume":"14","author":"Agarwala","year":"2004","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib76","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/annonc\/mdl009","article-title":"Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients","volume":"17","author":"Peters","year":"2006","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib77","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejso.2006.11.019","article-title":"Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma","volume":"33","author":"Siegel","year":"2007","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib78","first-page":"845","article-title":"[Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study]","volume":"27","author":"Cui","year":"2008","journal-title":"Ai Zheng"},{"issue":"93","key":"10.1016\/j.hoc.2024.08.010_bib79","first-page":"1157","article-title":"Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine","volume":"56","author":"Melichar","year":"2009","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib80","first-page":"300","article-title":"Liver metastases from melanoma: hepatic intra-arterial chemotherapy. A retrospective study","volume":"23","author":"Farolfi","year":"2011","journal-title":"J\u00a0Chemother"},{"issue":"12","key":"10.1016\/j.hoc.2024.08.010_bib81","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1055\/s-0031-1281743","article-title":"Transarterial hepatic chemoperfusion of uveal melanoma metastases: survival and response to treatment","volume":"183","author":"Heusner","year":"2011","journal-title":"Rofo"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib82","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib83","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/CMR.0000000000000343","article-title":"A\u00a0multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy","volume":"27","author":"Itchins","year":"2017","journal-title":"Melanoma Res"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib84","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jso.24984","article-title":"Hepatic artery infusion of melphalan in patients with liver metastases from ocular melanoma","volume":"117","author":"Boone","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2024.08.010_bib85","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/COC.0000000000000436","article-title":"Phase I\/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver","volume":"41","author":"Vera-Aguilera","year":"2018","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib86","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0960-7404(94)90005-1","article-title":"Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy","volume":"3","author":"Hafstrom","year":"1994","journal-title":"Surg Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib87","first-page":"3062","article-title":"A\u00a0phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver","volume":"6","author":"Alexander","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2024.08.010_bib88","first-page":"6343","article-title":"Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver","volume":"9","author":"Alexander","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/CMR.0b013e3282f8e3c9","article-title":"Isolated hepatic perfusion for liver metastases of malignant melanoma","volume":"18","author":"Rizell","year":"2008","journal-title":"Melanoma Res"},{"issue":"7","key":"10.1016\/j.hoc.2024.08.010_bib90","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1245\/s10434-008-9881-6","article-title":"Isolated hepatic perfusion with 200\u00a0mg melphalan for advanced noncolorectal liver metastases","volume":"15","author":"van Iersel","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.08.010_bib91","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1245\/s10434-010-0998-z","article-title":"Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma","volume":"17","author":"Varghese","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib92","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jso.23501","article-title":"Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience","volume":"109","author":"Forster","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib93","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1245\/s10434-015-4982-5","article-title":"Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion","volume":"23","author":"Ben-Shabat","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib94","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/CMR.0000000000000286","article-title":"Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres","volume":"26","author":"de Leede","year":"2016","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib95","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib96","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study","volume":"40","author":"Vogl","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib97","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease","volume":"117","author":"Karydis","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib98","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience","volume":"19","author":"Artzner","year":"2019","journal-title":"Cancer Imaging"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib99","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/07357900802620893","article-title":"A\u00a0first report of radioembolization for hepatic metastases from ocular melanoma","volume":"27","author":"Kennedy","year":"2009","journal-title":"Cancer Invest"},{"issue":"7","key":"10.1016\/j.hoc.2024.08.010_bib100","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jvir.2012.04.010","article-title":"Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization","volume":"23","author":"Piduru","year":"2012","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00270-012-0373-5","article-title":"Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients","volume":"36","author":"Klingenstein","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib102","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/CMR.0000000000000051","article-title":"Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience","volume":"24","author":"Memon","year":"2014","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib103","article-title":"A\u00a0single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma","volume":"4","author":"Schelhorn","year":"2015","journal-title":"Acta Radiol Open"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib104","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/COC.0000000000000033","article-title":"Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography","volume":"39","author":"Eldredge-Hindy","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/COC.0000000000000109","article-title":"Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study","volume":"40","author":"Xing","year":"2017","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2024.08.010_bib106","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/0284186X.2018.1465587","article-title":"Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience","volume":"57","author":"Tulokas","year":"2018","journal-title":"Acta Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2024.08.010_bib107","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jvir.2018.04.030","article-title":"Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series","volume":"29","author":"Zheng","year":"2018","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib108","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A\u00a0Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib109","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00270-019-02366-8","article-title":"Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization","volume":"43","author":"Levey","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib110","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2967\/jnumed.119.230870","article-title":"First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver","volume":"61","author":"Ponti","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"33","key":"10.1016\/j.hoc.2024.08.010_bib111","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1200\/JCO.2008.16.0705","article-title":"Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor","volume":"26","author":"Sato","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2024.08.010_bib112","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1477-7819-10-113","article-title":"Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma","volume":"10","author":"Alvarez-Downing","year":"2012","journal-title":"World J Surg Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.08.010_bib113","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/jdv.12405","article-title":"MR-guided laser-induced thermotherapy (LITT) in patients with liver metastases of uveal melanoma","volume":"28","author":"Eichler","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib114","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","article-title":"Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases","volume":"26","author":"Valsecchi","year":"2015","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib116","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.08.010_bib117","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1200\/JCO.1996.14.7.2083","article-title":"Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Rusthoven","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib118","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1200\/JCO.1998.16.5.1743","volume":"16","author":"Falkson","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib119","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9<1979::AID-CNCR15>3.0.CO;2-G","article-title":"A\u00a0phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma","volume":"85","author":"Agarwala","year":"1999","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.hoc.2024.08.010_bib121","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.hoc.2024.08.010_bib122","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib123","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hoc.2024.08.010_bib124","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.hoc.2024.08.010_bib125","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib126","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","article-title":"Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial","volume":"18","author":"Long","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2024.08.010_bib127","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10236","key":"10.1016\/j.hoc.2024.08.010_bib128","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.hoc.2024.08.010_bib129","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2024.08.010_bib130","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2024.08.010_bib131","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib132","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib","volume":"372","author":"Robert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.hoc.2024.08.010_bib133","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.08.010_bib134","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2024.08.010_bib135","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)","volume":"36","author":"Carvajal","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2024.08.010_bib136","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib137","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0959-8049(03)00132-1","article-title":"Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma","volume":"39","author":"Kivel\u00e4","year":"2003","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib138","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1634\/theoncologist.2015-0501","article-title":"Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma","volume":"21","author":"Piperno-Neumann","year":"2016","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib139","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CMR.0b013e3283403ce9","article-title":"Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma","volume":"20","author":"Homsi","year":"2010","journal-title":"Melanoma Res"},{"issue":"12","key":"10.1016\/j.hoc.2024.08.010_bib140","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/annonc\/mdl309","article-title":"A\u00a0randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma","volume":"17","author":"Schmittel","year":"2006","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.08.010_bib141","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10637-008-9143-2","article-title":"O-Mel-Inib: A Canc\u00e9ro-p\u00f4le Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma","volume":"26","author":"Penel","year":"2008","journal-title":"Investig New Drugs"},{"issue":"11","key":"10.1016\/j.hoc.2024.08.010_bib142","doi-asserted-by":"crossref","first-page":"e48787","DOI":"10.1371\/journal.pone.0048787","article-title":"Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512","volume":"7","author":"Bhatia","year":"2012","journal-title":"PLoS One"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2024.08.010_bib143","doi-asserted-by":"crossref","first-page":"9033","DOI":"10.1200\/jco.2014.32.15_suppl.9033","article-title":"Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial","volume":"32","author":"Piulats Rodriguez","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib144","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib145","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A\u00a0phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.hoc.2024.08.010_bib146","doi-asserted-by":"crossref","first-page":"viii443","DOI":"10.1093\/annonc\/mdy289.003","article-title":"1247PD -Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)","volume":"29","author":"Piulats Rodriguez","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.08.010_bib147","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.08.010_bib148","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/CMR.0b013e3283457743","article-title":"Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia","volume":"21","author":"Yi","year":"2011","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.hoc.2024.08.010_bib149","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CMR.0000000000000306","article-title":"Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma","volume":"27","author":"Shoushtari","year":"2017","journal-title":"Melanoma Res"},{"issue":"2","key":"10.1016\/j.hoc.2024.08.010_bib150","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis","volume":"35","author":"D\u2019Angelo","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2024.08.010_bib151","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1002\/cncr.30259","article-title":"The efficacy of anti-PD-1 agents in acral and mucosal melanoma","volume":"122","author":"Shoushtari","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib152","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.ejso.2019.06.036","article-title":"Iterative treatment with surgery and radiofrequency ablation of uveal melanoma liver metastasis: Retrospective analysis of a series of very long-term survivors","volume":"45","author":"Servois","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib153","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2024.08.010_bib154","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2024.08.010_bib155","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol"},{"issue":"31","key":"10.1016\/j.hoc.2024.08.010_bib156","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and Immune-Related Response in Solid Tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib157","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2024.08.010_bib158","first-page":"e90","article-title":"Prognostic Value of Low Tumor Burden in Patients With Melanoma","volume":"32","author":"Poklepovic","year":"2018","journal-title":"Oncology (Williston Park)"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824001035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824001035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:07:56Z","timestamp":1754597276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824001035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":158,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0889858824001035"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.08.010","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Overview of Liver Directed Locoregional Therapies","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}